The gap in overall life expectancy between people with HIV (PWH) and those without HIV has narrowed over time, particularly among optimally treated PWH. However, PWH still have fewer comorbidity-free years than those without HIV, according to a study presented at CROI 2020.
Patients with type 2 diabetes (T2D) who are also underweight have more than eightfold increased risk of active tuberculosis (TB), according to the Singapore Chinese Health Study, which highlights low BMI and diabetes as two independent risk factors for active TB disease.
Using the Fasting Algorithm for Singaporeans with Type 2 Diabetes (FAST) management tool improved glycaemic control among individuals with type 2 diabetes (T2D) who fasted during Ramadan, a recent study showed.
Adding liraglutide to first-line lifestyle therapy led to a significantly reduced BMI standard-deviation score (BMI SDS*) among obese adolescents who failed to respond to lifestyle therapy alone, according to a study presented at ENDO 2020.
The investigational, oral formulation of octreotide appeared to be effective and safe as maintenance treatment for adults with acromegaly, according to the results of the phase III OPTIMAL* study presented at ENDO 2020.
Use of thyroid replacement therapy in older people with isolated elevations in TSH* was associated with a significantly increased risk of death than those who were left untreated, according to the BLSA** study presented at ENDO 2020 — which raises the possibility of overtreatment in these older adults.
The human monoclonal anti-IGF-1R* antibody teprotumumab was effective in reducing proptosis or eye bulging in patients with the rare thyroid eye disease (TED) regardless of age, gender, and/or smoking status, according to pooled data presented at ENDO 2020.
Maintaining a good control of blood glucose level may slow down the decline of cognitive function in patients with type 2 diabetes (T2D) after a lacunar stroke, suggests a post hoc analysis of the SPS3* trial presented at the ENDO 2020 Virtual Meeting.